Similarly, Li et al. [59] demonstrated that IGF2BP2 can recognize and combine with the RNA methylation modification written by METTL3 to inhibit the degradation of SOX2, thereby promoting tumor progression. The gene discussed is METTL3; the disease is neoplasm.